Next Article in Journal
Emerging Role of the Slit/Roundabout (Robo) Signaling Pathway in Glioma Pathogenesis and Potential Therapeutic Options
Previous Article in Journal
Nucleoside Analogs in ADAR Guide Strands Enable Editing at 5′-GA Sites
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 14
Issue 10
10.3390/biom14101230
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Boosting Serotonin Synthesis Is Not Sufficient to Improve Motor Coordination of Mecp2 Heterozygous Mouse Model of Rett Syndrome

by
Claudia Villani
,
Giuseppina Sacchetti
and
Roberto W. Invernizzi
*
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156 Milan, Italy
*
Author to whom correspondence should be addressed.
Biomolecules 2024, 14(10), 1230; https://doi.org/10.3390/biom14101230
Submission received: 30 July 2024 / Revised: 5 September 2024 / Accepted: 27 September 2024 / Published: 29 September 2024
(This article belongs to the Special Issue Molecular Advances in Rett Syndrome and Other Chromatin Related Disorders)
Browse Figures
Review Reports Versions Notes

Abstract

:
Motor deficit is a core symptom of Rett syndrome, a rare neurological disease caused in most cases by mutations of the methyl-CpG-binding protein2 (MECP2) gene. Serotonin reuptake inhibitors improve motor coordination in Mecp2 heterozygous (Het) mice and serotonin depletion prevented this effect. Here, we assess alterations in indole levels in various brain regions and whether boosting brain serotonin synthesis with the serotonin precursors tryptophan, 5-hydroxytryptophan and α-lactalbumin rescued motor coordination deficit of Mecp2 Het mice. Motor coordination was assessed in the accelerated rotarod during and after systemic administration of serotonin precursors for 2–3 weeks. Since no data are available, the effect of α-lactalbumin on tryptophan, serotonin and 5-hydroxyindoleacetic acid levels was evaluated in various brain regions in order to identify the dose of ALAC to evaluate on motor coordination. As compared to WT, Mecp2 Het mice show reduced levels of serotonin in the whole brain, hippocampus, brainstem and cerebral cortex, but not the striatum. Reduced levels of 5-hydroxyindoleacetic acid were observed in the hippocampus and brainstem. Doses of serotonin precursors increasing brain tryptophan and/or serotonin production and metabolism had no effect on motor coordination. The results indicate that boosting serotonin synthesis is not sufficient to improve motor coordination of Mecp2 Het mice.

Graphical Abstract

1. Introduction

Motor skill impairment is one of the core symptoms of Rett syndrome (RTT), a rare neurological disease caused in most cases by loss-of-function mutations of the methyl-CpG-binding protein 2 gene (MECP2; Mecp2 in rodents) [1]. Motor symptoms observed in patients, including limited motility, ataxic gait, motor incoordination and tremors, are reproduced in most mouse models of the syndrome, with a good degree of face validity [2]. Low levels of serotonin (5-HT; 5-hydroxytryptamine), tryptophan hydroxylase 2 (tph2) expression and 5-hydroxyindoleacetic acid (5-HIAA), the main metabolite of 5-HT, are found in brain tissue and/or cerebrospinal fluid of RTT patients carrying MECP2 mutations [3]. Consistently, alterations of brain levels, synthesis and release of 5-HT, and 5-HT receptor expression and function are observed in Mecp2 null mouse models of RTT [4,5,6,7,8]. The limited information available in female Mecp2 Het mice shows reduced tissue levels of 5-HT in the hippocampus but not in the raphe area [9], while no changes are found in brain 5-HT synthesis and cortical extracellular levels under basal condition or in response to a challenge dose of the selective 5-HT reuptake inhibitor (SSRI) fluoxetine [4].
Experimental studies in female Mecp2 mutant mice show an improvement of motor, cognitive and respiratory symptoms in response to 5-HT receptor agonists and drugs enhancing the endogenous tone of 5-HT at brain synapses such the SSRIs and the mixed serotonergic and noradrenergic antidepressant mirtazapine [10,11,12]. Case reports support the potential use of serotonergic drugs including fluoxetine, 5-HT1A receptor agonists or their combination for the treatment of respiratory deficits and stereotypies in patients with RTT [13,14,15] and SSRIs are considered the most effective drugs for the treatment of psychiatric symptoms of RTT [16].
We recently showed that repeated but not single administration of fluoxetine abolishes the motor coordination deficit in female Mecp2 Het mice and enhances the expression of the MeCP2 protein in several regions of Mecp2 Het mice [4,17]. These effects were no longer present after serotonin depletion with the 5-HT synthesis inhibitor p-chlorophenylalanine [4,17] suggesting that 5-HT plays a key role in rescuing motor coordination impairment. However, some of the effects of fluoxetine, such as its action on ionic channels and neurosteroid synthesis, are independent of endogenous 5-HT [18,19]. Thus, it is not yet clear whether the enhancement of brain 5-HT transmission is in itself sufficient to rescue motor coordination deficit of Mecp2 Het mice or other factors may contribute.
Brain 5-HT synthesis depends, among other factors, on the brain concentration of the amino acid precursor tryptophan (TRP), an essential amino acid and physiological substrate of Tph2, the rate-limiting enzyme in the synthesis of brain 5-HT [20]. Unfortunately, the efficacy of 5-HT precursors in increasing brain 5-HT is limited by their short half-life in humans and rodents [21,22,23] and gastrointestinal adverse effects may occur when relatively high doses of TRP and 5-hydroxytryptophan (5-HTP) are used to overcome their short-lasting effect [24].
α-lactalbumin (ALAC), a whey protein rich in tryptophan [25], is well tolerated and safely used to supports adequate growth in infants [26,27]. Prolonged ingestion of ALAC increased the ratio of TRP/large neutral amino acids (LNAAs) in human plasma, which favoured the entry of TRP into the brain. In addition, ALAC increased cortical TRP levels and 5-HT synthesis and release in the rat hypothalamus [28,29,30,31]. ALAC (250–1000 mg/kg) was effective in several models of epilepsy in rats and mice, and counteracted depressive-like behaviour and intestinal inflammation in mice [30,31,32]. Thus, ALAC may be an alternative to TRP and 5-HTP to increase brain 5-HT synthesis/levels, with a safer profile of side effects.
The present study aims to provide further evidence on the alteration of 5-HT levels and metabolism and to evaluate the role of different 5-HT precursors in improving motor coordination in Mecp2 Het mice. Since no data are available in the mouse, we assessed the effect of ALAC on brain indoles in order to establish the dose increasing brain TRP and 5-HT levels and metabolism to be used in a subsequent motor test in Mecp2 Het mice.

2. Materials and Methods

2.1. Experimental Design and Statistics

Breeding pairs, consisting of female Mecp2 Het (B6.129P2(C)-Mecp2tm1.1Bird/J; stock: 003890) and male C57BL/6J (stock: 000664) mice, were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Details of mice breeding and husbandry are described elsewhere [4]. All experimental data were obtained in female mice. As outlined in Figure 1, different cohorts of mice were used to identify alterations of brain monoamines and tryptophan in Mecp2 Het mice as compared to WT, the effects of ALAC on brain monoamines and brain and plasma tryptophan and the ability of 5-HT precursors to counteract the motor coordination deficit of Mecp2 Het mice.
Cohort 1 was used to assess differences in indole levels in the brain and selected brain areas of untreated WT and Mecp2 Het mice. Cohort 1 was composed of 4 WT and 6 Mecp2 Het mice aged 23–26 weeks. The dose- and time-dependent effects of a single oral administration of ALAC on brain and plasma levels of TRP and brain levels of indoles was assessed in 51 WT mice (Cohort 2a). Additional Mecp2 Het mice (n = 10) were used to compare the efficacy of a single oral dose of ALAC (8000 mg/kg) in increasing plasma and brain levels of TRP and brain indole levels in WT (n = 12) and Mecp2 Het mice (Cohort 2b). Cohort 2c consisted of 12 WT and 12 Mecp2 Het mice aged 16–24 weeks given TRP once daily for 14 days and euthanised 1 h after the last dose of the chronic schedule to evaluate changes in brain TRP, 5-HT and 5-HIAA levels after chronic administration. The effect of TRP and 5-HTP on motor coordination was assessed in Cohort 3 mice, which included 34 wild type (WT) and 31 Mecp2 Het mice aged 16–20 weeks. Mice were given TRP intraperitoneally once daily for 14 days and their performance on the rotarod was assessed 30–90 min after TRP administration. 5-HTP was administered in the drinking water, which was freely available during the 14 days of treatment. Rotarod performance of mice receiving TRP, 5-HTP or the respective vehicle was assessed 1, 3, 7 and 14 days after treatment.
The effect of ALAC on motor coordination was assessed in a cohort of mice consisting of 10 WT and 19 Mecp2 Het mice aged 18–23 weeks (Cohort 4). ALAC was administered in the drinking water, freely available during the 21 days of treatment, and the latency to fall from the rotarod was assessed 1, 7, 14 and 21 days after treatment.
The effect of the various treatments on the rotarod (4–40 rpm in 300 s; Ugo Basile, Italy), was assessed in WT and Mecp2 Het mice. On each testing day, mice underwent 4 trials interspersed by at least 15 min resting in the home cage between one trial and another. Mice were tested on the rotarod between 8:30 and 11:00 a.m. (in mice given TRP, the first trial started 30 min after injection). Figure 1 shows the schedule of treatment and the timing of behavioural assessments.
Mice were allocated to experimental groups by age-stratified randomization. The experimenter assessing rotarod performance was not blind to treatments.
Statistical analysis was performed using GraphPad Prism version 10.1.2 (GraphPad Software, Boston, MA, USA) or Stat-View 5.0 (SAS Institute Inc., Cary, NC, USA). One-way ANOVA followed by Dunnett’s test was used to compare the dose- and time-dependent effect of ALAC on TRP, 5-HT and 5-HIAA in WT mice. The effect of 8000 mg/kg ALAC on indole and TRP levels in Mecp2 Het in comparison to WT mice were analysed by two-way ANOVA with genotype and treatment as between-subject factors, followed by Sidak’s test. Indole levels in untreated WT and Mecp2 Het mice were compared by Student’s t-test.
The mean latency to fall of four daily trials was calculated for each mouse and compared across the experimental groups by 3-way ANOVA or a mixed-effects model, with days of treatment as a within-subject factor and genotype and treatment as between-subject factors. If ANOVA revealed a significant effect of treatment or an interaction treatment × genotype or treatment × time, further analyses were carried out to compare the effect of each treatment versus vehicle with Sidak’s test. Raw data are available in Zenodo (https://zenodo.org/uploads/13134000).

2.2. Drug Treatment

L-tryptophan (Fluka, Buchs, Switzerland) was dissolved in a minimal volume of 1 M NaOH and diluted with sterile, pyrogen-free water. The pH of the solution was adjusted to 6.5–7.0 with 1 M HCl. Appropriate volumes of concentrated (10×) phosphate buffered saline (Lonza, Belgium) was added and the solution was brought to final volume with pyrogen-free water. Mice received 300 mg/kg tryptophan or an equivalent volume (20 mL/kg) of vehicle intraperitoneally (i.p.) between 8:00 and 10:00 a.m., during the light phase of the light-dark cycle (light on at 7:00 a.m.). 5-HTP (Alfasigma, Italy) and ALAC (Dermolife, Italy) were dissolved and administered in drinking water. As 5-HTP solution is light-sensitive, drinking bottles were protected from light by covering them with aluminium foil and replaced daily. Bottles filled with ALAC solution were replaced with clean bottles containing fresh ALAC solution every 2–3 days. Mice had free access to bottles containing 5-HTP, ALAC or plain water 24 h a day. The mean fluid intake per mouse, expressed as the total volume of fluid consumed per cage (n = 2–4 mice/cage) and per day, was monitored by weighing the bottles every day (5-HTP) or every 2–3 days (ALAC). If mean fluid intake varied by more than 20%, the concentration of ALAC or 5-HTP was adjusted to keep constant the daily drug intake. The doses of TRP (300 mg/kg/day) and 5-HTP (100 mg/kg/day) used in the present study were previously shown to enhance brain 5-HT levels, synthesis and/or release in WT mice and in mice with reduced Tph2 activity [24,33].

2.3. Monoamines and Tryptophan Assay

Mice were euthanised by decapitation under deep anaesthesia (ketamine/medetomidine 75/1, mg/kg i.p.) between 9:00 and 12:00 a.m. (with the exception of the mice used to evaluate the effect of ALAC 8 h after administration, which were euthanised at 4 p.m.). Ketamine HCl (Lobotor) and medetomidine HCl (Domitor) were purchased from ACME SRL, Italy and Vetoquinol, Italy, respectively. The brain was rapidly removed from the skull and positioned on a refrigerated aluminium plate. The cerebellum was removed and the brain was divided into two hemispheres with a cut along the sagittal line. Half the brain was immediately frozen on dry ice. The cerebral cortex, hippocampus, striatum and brainstem were dissected freehand from the remaining hemisphere and frozen on dry ice. Trunk blood (0.5–1.0 mL) was collected in 1.5 mL tubes containing 5 mg NaF and 7 mg Na2EDTA·2H2O (Milian, Switzerland) to prevent clotting and stored at 4 °C for 30 min. Plasma was separated by centrifugation at 5000× g for 10 min, at 4 °C with an Eppendorf 5417R centrifuge (Eppendorf, Milan, Italy) and stored at −70 °C until analysis. Brain tissues were weighed, transferred to Eppendorf 3810 tubes and stored at −70 °C until analysis. Brain tissues were homogenized in 10 volumes (20 volumes for striatum and hippocampus) 0.1 M HClO4 (Carlo Erba, Milan, Italy) containing 0.1% Na2EDTA·2H2O (Sigma-Aldrich, Milan, Italy), 0.05% Na2S2O5 (Carlo Erba, Milan, Italy) and 0.002% ascorbic acid (Sigma-Aldrich, Milan, Italy) by an ultrasonic homogeniser (Sonoplus HD2070, Bandelin, Berlin, Germany). Homogenates were centrifuged (12,000× g for 10 min at 4 °C) with an Avanti J-E centrifuge (Beckman-Coulter, Cassina de’ Pecchi, Italy). The supernatant was filtered through 0.45 μm PVDF syringe filters (Perkin Elmer, Milan, Italy) and split into 2 aliquots for the determination of indoles and TRP, by reverse-phase high performance liquid chromatography coupled with electrochemical detection. Briefly, indoles were separated by a reverse phase column (Kinetex® 2.6 µm C18 100 Å, LC Column 75 × 3 mm, Phenomenex, Bologna, Italy). The mobile phase consisted of 3.0 g/L sodium acetate·3H2O (Merck, Darmstadt, Germany), 5 g/L citric acid monohydrate (Merck, Darmstadt, Germany), 37 mg/L Na2EDTA·2H2O (Sigma-Aldrich, Italy), 250 mg/L sodium heptane sulfonate (Sigma-Aldrich, Milan, Italy). The pH of the solution was adjusted to 3.5 before the addition of 8% CH3OH (Merck, Darmstadt, Germany). The flow rate of the mobile phase was maintained at 0.4 mL/min with a LC-20AD isocratic pump (Shimadzu, Milan, Italy). The electrochemical detector (Coulochem II; ESA, Chemsford, MA, USA) was equipped with a 5011 analytical cell (E1 = 0 mV; E2 = +300 mV). Total levels of TRP in the half brain, brain regions and plasma were determined as previously described [34].

3. Results

3.1. Brain Levels of Monoamines and Tryptophan in Female WT and Mecp2 Het Mice

5-HT, 5-HIAA and TRP levels in the whole brain and various brain regions were compared in WT and Mecp2 Het mice (Table 1).
Mecp2 Het mice aged 23–26 weeks at the time of sacrifice show reduced levels of brain 5-HT, but no significant changes in brain 5-HIAA and TRP in the whole brain. Regional analysis of monoamine levels showed a reduction of about 20% of 5-HT in the hippocampus, cerebral cortex and brainstem, while no significant changes were observed in the striatum. 5-HIAA levels were reduced in the hippocampus and brainstem by 20% and 11%, respectively, but no reduction was observed in the cerebral cortex and striatum.
Table 1. Levels of 5-HT, 5-HIAA and TRP in the whole brain and brain regions of WT and Mecp2 Het mice.
Table 1. Levels of 5-HT, 5-HIAA and TRP in the whole brain and brain regions of WT and Mecp2 Het mice.
5-HT5-HIAATRP
ng/gng/gμg/g
BRAIN
WT (4) 839 ± 26456 ± 264.5 ± 0.2
HET (6) 679 ± 21391 ± 244.5 ± 0.3
t(df)4.763(8)1.803(8)0.0795(8)
p0.00140.1090.938
HIPP
WT (4) 792 ± 43505 ± 215.2 ± 0.3
HET (6) 617 ± 49407 ± 184.9 ± 0.2
t(df)2.484(8)3.521(8)0.8481(8)
p0.03790.00780.8481
CTX
WT (4) 709 ± 19285 ± 83.3 ± 0.1
HET (6) 580 ± 26263 ± 133.6 ± 0.2
t(df)3.607(8)1.284(8)1.169(8)
p0.00690.23510.2761
BST
WT (4) 1063 ± 37556 ± 243.8 ± 0.1
HET (6) 817 ± 34493 ± 134.2 ± 0.2
t(df)4.778(8)2.549(8)1.290(8)
p0.0140.03420.2332
STR
WT (4) 674 ± 104403 ± 555.0 ± 0.1
HET (5) 601 ± 68364 ± 245.0 ± 0.4
t(df)0.7250(7)0.6720(7)0.0668(7)
p0.4920.52310.9486
Data are mean ± SEM. The number of mice/group is shown in parentheses. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine; BST, brainstem; CTX, cerebral cortex; HET, Mecp2 Het; HIPP, hippocampus; STR, striatum; TRP, tryptophan WT, wild type. Bold type indicates a significant difference vs. WT (Student’s t-test). T-values, degrees of freedom (df) and associated probability (p) are indicated in italics.

3.2. Dose-Dependent Effect of Single Oral Doses of ALAC on Plasma and Brain Levels of TRP and Brain Levels of 5-HT and 5-HIAA in WT Mice

To evaluate the effect of ALAC on brain indoles, WT mice were treated with single doses of 250–8000 mg/kg per os. The dose of ALAC increasing brain TRP and indoles in WT mice (8000 mg/kg) was subsequently evaluated in Mecp2 Het mice to confirm its efficacy in mutant mice.
The dose-dependent effect of ALAC on plasma and brain TRP levels and brain 5-HT and 5-HIAA levels in WT mice is shown in Figure 2. A single administration of 8000 mg/kg ALAC significantly increased TRP levels in the plasma (F3,16 = 30.05; p < 0.0001; one-way ANOVA) and brain (F3,15 = 13.57; p = 0.0002; one-way ANOVA) of WT mice 2 h after the administration, reaching 323% and 279% of control levels, respectively. Lower doses had no significant effect. At 8000 mg/kg, ALAC significantly increased brain levels of 5-HT (115% of control levels; F3,16 = 9.032; p = 0.001; one-way ANOVA) and 5-HIAA (142% of control levels; F3,15 = 20.66; p < 0.0001; one-way ANOVA) in WT mice. Lower doses of ALAC had no significant effect on brain 5-HT and 5-HIAA.
Biomolecules 14 01230 g002
Figure 2. Dose-dependent effect of single oral doses of α-lactalbumin (ALAC; 250–8000 mg/kg) on plasma and brain tryptophan (TRP) and brain 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels in wild type mice. Data are mean ± SEM of 3–6 mice/group. Solid circles, squares and triangles represent individual data. F-values (one-way ANOVA) are shown in Results. ** p = 0.0095; *** p < 0.0001 vs. vehicle (0 mg/kg), Dunnett’s test.
Figure 2. Dose-dependent effect of single oral doses of α-lactalbumin (ALAC; 250–8000 mg/kg) on plasma and brain tryptophan (TRP) and brain 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels in wild type mice. Data are mean ± SEM of 3–6 mice/group. Solid circles, squares and triangles represent individual data. F-values (one-way ANOVA) are shown in Results. ** p = 0.0095; *** p < 0.0001 vs. vehicle (0 mg/kg), Dunnett’s test.
Biomolecules 14 01230 g002

3.3. Time-Dependent Effect of ALAC on Plasma and Brain Levels of TRP and Brain Levels of 5-HT and 5-HIAA in WT Mice

Figure 3 shows the time-dependent effect of a single oral dose of ALAC (8000 mg/kg) on plasma and brain levels of TRP and brain levels of 5-HT and 5-HIAA in WT mice. ALAC significantly increased TRP in plasma (F4,24, 90.39; p < 0.0001) and brain (F4,24, 23.98; p < 0.0001) and brain 5-HT (F4,24, 7.158; p = 0.0006) 1 and 2 h after administration. A significant increase in 5-HIAA (F4,24, 19.99; p < 0.0001) was observed only 2 h after ALAC administration. Plasma TRP levels were maximally increased 1 h after dosing, while brain TRP, 5-HT and 5-HIAA increased to a similar extent 1 or 2 h after administration. ALAC had no effect on TRP, 5-HT and 5-HIAA levels 4 and 8 h after dosing.
Biomolecules 14 01230 g003
Figure 3. Time-dependent effect of a single oral dose of α-lactalbumin (ALAC; 8000 mg/kg) on plasma and brain levels of tryptophan (TRP) and brain levels of 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) in wild type mice. F-values (one-way ANOVA) are shown in Results. Data are mean ± SEM of 5–7 mice/group. ** p < 0.002; *** p < 0.0001 (Dunnett’s test).
Figure 3. Time-dependent effect of a single oral dose of α-lactalbumin (ALAC; 8000 mg/kg) on plasma and brain levels of tryptophan (TRP) and brain levels of 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) in wild type mice. F-values (one-way ANOVA) are shown in Results. Data are mean ± SEM of 5–7 mice/group. ** p < 0.002; *** p < 0.0001 (Dunnett’s test).
Biomolecules 14 01230 g003

3.4. Effect of 8000 mg/kg ALAC on Plasma and Brain Levels of TRP and Brain Levels of 5-HT and 5-HIAA in WT and Mecp2 Het Mice

Figure 4 shows the effect of a single oral dose of ALAC (8000 mg/kg) on plasma and brain levels of TRP and brain levels of 5-HT and 5-HIAA in WT and Mecp2 Het mice. ALAC significantly increased plasma and brain levels of TRP in WT mice reaching 323% and 279% of control mice, respectively. ALAC had a similar effect in Mecp2 Het mice where the increase in TRP reached 349% and 313% of control values in plasma and brain, respectively. Two-way ANOVA showed a significant effect of treatment on plasma (F1,18 = 118.8, p < 0.0001) and brain (F1,18 = 43.43, p < 0.0001) TRP, but no significant effects of genotype (Plasma, F1,18= 1.582, p = 0.2246; Brain, F1,18 = 1.709, p = 0.2076) and genotype × treatment interaction (Plasma, F1,18 = 0.1621, p = 0.6920; Brain, F1,18 = 0.2584, p = 0.6174). ALAC significantly increased brain levels of 5-HIAA in WT mice (142% of control values) and in Mecp2 Het mice (129% of control values). Two-way ANOVA showed a significant effect of treatment (F1,18 = 26.46, p < 0.0001), genotype (F1,18 = 22.69, p = 0.0002) but not genotype × treatment interaction (F1,18 = 2.323, p = 0.1449). ALAC significantly increased brain levels of 5-HT in WT (115% of control values) but had no significant effect in Mecp2 Het mice. Two-way ANOVA showed a significant effect of treatment (F1,18 = 10.67, p = 0.0043), genotype (F1,18 = 22.57, p = 0.0002) but not genotype × treatment interaction (F1,18 = 2.213, p = 0.1542).
Biomolecules 14 01230 g004
Figure 4. Effect of a single oral dose of α-lactalbumin (ALAC; 8000 mg/kg) on plasma and brain levels of tryptophan (TRP) and brain levels of serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) in wild type (WT) and Mecp2 Het (HET) mice. Data are mean ± SEM of 5–6 mice/group. Solid circles and triangles represent individual data. F-values (two-way ANOVA) are shown in Results. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 vs. vehicle (Sidak’s test).
Figure 4. Effect of a single oral dose of α-lactalbumin (ALAC; 8000 mg/kg) on plasma and brain levels of tryptophan (TRP) and brain levels of serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) in wild type (WT) and Mecp2 Het (HET) mice. Data are mean ± SEM of 5–6 mice/group. Solid circles and triangles represent individual data. F-values (two-way ANOVA) are shown in Results. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 vs. vehicle (Sidak’s test).
Biomolecules 14 01230 g004

3.5. Effect of Repeated Treatment with Tryptophan on Brain Levels of TRP, 5-HT and 5-HIAA in WT and Mecp2 Het Mice

Table 2 shows the effect of TRP given i.p. once daily for 14 days on brain levels of TRP, 5-HT and 5-HIAA. Administration of exogenous TRP increased brain levels of TRP by 2858% and 2466% of control values in WT and Mecp2 Het mice, respectively. Brain levels of 5-HT and 5-HIAA significantly increased in response to repeated administration of TRP reaching 129% and 240% of control values in WT and 139% and 219% in Mecp2 Het mice. Two-way ANOVA showed a significant effect of treatment for TRP, 5-HT and 5-HIAA, a significant effect of genotype for 5-HT, but no significant effect of genotype x treatment interaction for TRP and indoles.
Table 2. Brain levels of TRP, 5-HT and 5-HIAA in WT and Mecp2 Het mice receiving repeated doses of TRP for 14 days.
Table 2. Brain levels of TRP, 5-HT and 5-HIAA in WT and Mecp2 Het mice receiving repeated doses of TRP for 14 days.
TRP5-HT5-HIAA
μg/gng/g tissueng/g tissue
WT-Veh (5)3.4 ± 0.4601 ± 31668 ± 74
WT-TRP (7)97.2 ± 6.3 ***773 ± 29 **1602 ± 114 ***
HET-Veh (6)3.5 ± 0.2631 ± 18613 ± 31
HET-TRP (6)86.3 ± 8.2 ***876 ± 41 ***1343 ± 89 ***
F treatment (df), p248.4 (1,20), p < 0.000144.33 (1,20), p < 0.000189.41 (1,20), p < 0.0001
F genotype (df), p0.9199 (1,20), p = 0.34904.543 (1,20), p = 0.04573.176 (1,20), p = 0.0899
F interaction (df), p0.9581 (1,20), p = 0.33941.406 (1,20), p = 0.24971.330 (1,20), p = 0.2623
Mice received 300 mg/kg tryptophan intraperitoneally once daily for 14 days and were euthanised 1h after the last dose of the chronic schedule. Data are mean ± SEM. The number of mice/group is shown in parentheses. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine; HET, Mecp2 Het; TRP, tryptophan; Veh, vehicle; WT, wild type. F values (two-way ANOVA), degrees of freedom (df) and associated probability (p) are indicated in italics. ** p = 0.005, *** p < 0.0001 vs. respective vehicle (Tukey’s multiple comparisons test).

3.6. Effect of TRP, 5-HTP and ALAC on Rotarod Performance in Mecp2 Het Mice

The effect of TRP and 5-HTP on the latency to fall from the accelerated rotarod was examined in WT and Mecp2 Het mice at various time points after administration (Figure 5). As previously reported [4], the performance of untreated Mecp2 Het mice in the rotarod is much lower than in WT mice (mean latency to fall: Mecp2 Het, 159 ± 7 and WT, 273 ± 4 s). Consistently, ANOVA showed a highly significant effect of genotype (F1,59 = 98.143, p < 0.0001).
TRP and 5-HTP had no significant effect on the latency to fall of WT and Mecp2 Het mice at any times after treatment (Figure 5). Three-way ANOVA showed a significant effect of days (F4,236 = p = 0.0037), but no effects of treatment (F2,59 = 1.591, p = 0.2123), genotype × treatment (F2,59 = 1.113, p = 0.3354), days × genotype (F4,236 = 2.328, p = 0.0569), days × treatment (F8,236 = 0.549, p = 0.8189) and days × genotype × treatment (F8,236 = 0.688, p = 0.7019) interaction.
Biomolecules 14 01230 g005
Figure 5. Effect of tryptophan (TRP; 300 mg/kg, once daily) and 5-hydroxytryptophan (5-HTP; 100 mg/kg/day in drinking water) on the latency to fall from the accelerated rotarod in wild type (WT) and Mecp2 Het (HET) mice. F-values (three-way ANOVA) are shown in Results. Each time-point is the mean ± SEM of four daily trials. The number of mice per group is shown in parentheses. B (basal), latency to fall before the start of treatment; Veh, vehicle.
Figure 5. Effect of tryptophan (TRP; 300 mg/kg, once daily) and 5-hydroxytryptophan (5-HTP; 100 mg/kg/day in drinking water) on the latency to fall from the accelerated rotarod in wild type (WT) and Mecp2 Het (HET) mice. F-values (three-way ANOVA) are shown in Results. Each time-point is the mean ± SEM of four daily trials. The number of mice per group is shown in parentheses. B (basal), latency to fall before the start of treatment; Veh, vehicle.
Biomolecules 14 01230 g005
ALAC had no effect on the latency to fall of WT and Mecp2 Het mice at any times after administration (Figure 6). Three-way ANOVA showed a significant effect of genotype (F1,25 = 13.277, p = 0.0012), but not treatment (F1,25 = 0.022, p = 0.8844), days (F4,100 = 1.047, p = 3871), genotype × treatment (1,25 = 0.002. p = 0.9675), days × genotype (F4,100 = 0.768, p = 0.5487), days × treatment (F4,100 = 0.154, p = 0.9608) and days × genotype × treatment (F4,100 = 0.053, p = 0.9946) interaction.
Biomolecules 14 01230 g006
Figure 6. Effect of α-lactalbumin (ALAC; 8000 mg/kg/day in drinking water) in the accelerated rotarod in wild type (WT) and Mecp2 Het (HET) mice. F-values (three-way ANOVA) are shown in Results. Each time-point is the mean ± SEM of four daily trials. The number of mice per group is shown in parentheses. B (basal), latency to fall before the start of treatment.
Figure 6. Effect of α-lactalbumin (ALAC; 8000 mg/kg/day in drinking water) in the accelerated rotarod in wild type (WT) and Mecp2 Het (HET) mice. F-values (three-way ANOVA) are shown in Results. Each time-point is the mean ± SEM of four daily trials. The number of mice per group is shown in parentheses. B (basal), latency to fall before the start of treatment.
Biomolecules 14 01230 g006

4. Discussion

This study demonstrates that 5-HT and 5-HIAA levels are reduced in adult Mecp2 Het mice (5–6 months of age) and shows that treatment with 5-HT precursors does not modify the motor coordination deficit of Mecp2 Het mice.
Although the reduction in 5-HT and 5-HIAA levels in the hippocampus of Mecp2 Het mice confirm previous findings [9], to our knowledge no other studies assessed whether alterations of 5-HT homeostasis occur in the brain of female Mecp2 Het mice. As compared to WT, Mecp2 Het mice show lower levels of hippocampal, brainstem and cortical 5-HT. This indicates that 5-HT deficiency, albeit small, is widespread across different brain regions except the striatum where no differences are found between genotypes. The reduction in 5-HT levels and metabolism is small and likely not sufficient to account for the motor coordination deficit. Consistently, genetically and pharmacologically induced depletion of brain 5-HT has no effect on rotarod performance in WT mice and does not affect the motor coordination impairment of Mecp2 Het mice [4,35]. As in previous studies in male Mecp2 null mice [6,7], we found no changes in 5-HT and 5-HIAA in the striatum of Mecp2 Het mice.
Several hypotheses have been advanced on the causes of brain 5-HT deficit observed in RTT patients and mouse models of the disease. These include reduced 5-HT innervation, production, reuptake and metabolism of 5-HT [6]. Although the role of these factors was not systematically addressed in the present study, data presented here and in other published papers may help clarify the role of some of these factors. We found no changes in TRP levels in any brain region investigated. Therefore, the reduced 5-HT levels are not caused by deficiency of the endogenous precursor. Reduced tph2 gene expression has been found in male mice globally lacking the Mecp2 gene and in mice with selective deletion of the gene in 5-HT neurons [3]. However, another study found no reduction in tph2 expression in raphe nuclei of Mecp2 null mice [6] and data on tph2 expression in female heterozygous mice are lacking. We measured the levels of 5-HTP after l-aromatic amino acid decarboxylase inhibition, an indicator of 5-HT synthesis [36], and found no differences between WT and Mecp2 Het mice in 5-HTP accumulation in the hippocampus, striatum, brainstem, prefrontal cortex and the rest of the cerebral cortex [4]. Thus, the low levels and metabolism of 5-HT found in most brain regions of adult Mecp2 Het mice unlikely reflects reduced 5-HT synthesis.
No differences in cortical 5-HT innervation, synaptic markers and expression of 5-HT-related genes such as the serotonin transporter and monoamine oxidase, which may have marked effects on 5-HT storage and metabolism, have been observed in Mecp2 null mice and no data are available in Mecp2 Het mice [6,8]. Thus, the factors contributing to the reduction in indole levels observed in Mecp2 Het mice remain largely unknown.
5-HT plays a key role in fluoxetine’s ability to rescue motor coordination impairment of Mecp2 Het mice [4]. Based on this finding, we expected that 5-HT precursors may mimic the ability of fluoxetine to rescue motor coordination deficit in Mecp2 Het mice but the data presented here do not support this hypothesis.
It is unlikely that the lack of effect of 5-HT precursors is due to underdosing as previous studies clearly showed that doses of TRP and 5-HTP similar to those used in the present study or lower increase the production and release of brain serotonin. In addition, TRP and 5-HTP restored normal 5-HT levels in mice with reduced function or total deletion of the Tph2 gene [24,33,37,38,39,40,41].
Here, we provide evidence that a single dose of 8000 mg/kg ALAC increased brain levels of TRP in Mecp2 Het mice by more than 3-fold. Brain 5-HT levels are only marginally increased by ALAC, while a larger effect is found on brain 5-HIAA, which indicates that ALAC stimulates the synthesis and metabolism of 5-HT. However, these effects are much lower than those achieved after the administration of 300 mg/kg TRP once daily for 14 days under the same experimental conditions used to assess the effect of TRP on motor coordination. Since repeated dosing of TRP had no effect on motor coordination, it is reasonable to conclude that boosting 5-HT synthesis is not sufficient to counteract the motor coordination deficit of Mecp2 Het mice. Consistently, rats ingesting diets enriched in ALAC (roughly 4–30 g/kg/day) show increased brain TRP and 5-HT levels, synthesis and release of 5-HT [29,42]. According to dose translation from animal to human studies using the body surface area normalization method [43], 8000 mg/kg ALAC as used in this study is comparable to the dose increasing TRP in human plasma both in terms of effectiveness and duration [44]. To our knowledge, this is the first study providing information on dose- and time-dependent effect of ALAC on mouse brain and plasma TRP and brain 5-HT and 5-HIAA levels. Data clearly show that doses of ALAC lower than 8000 mg/kg do not affect brain and plasma TRP and brain levels and metabolism of 5-HT. This suggests that the effects of lower doses of ALAC as used in previous mouse studies can hardly be attributed to changes in TRP and 5-HT availability in the brain and peripheral organs.
5-HT plays an important role in early neuronal development and function including neuronal proliferation, migration and differentiation as well as motor skills [45,46,47]. Thus, it cannot be excluded that the administration of 5-HT precursors during the neonatal period or early childhood may be more effective in improving motor coordination in Mecp2 Het mice compared to administration in adults.
Motor coordination improvement in Mecp2 Het mice takes about a week to develop after fluoxetine or citalopram [4]. This suggests that adaptive changes developing over time likely underlie the ability of SSRIs to rescue motor coordination deficit. Consistently, changes in neuronal excitability, protein synthesis, plasticity or neurogenesis have been involved in the mechanisms facilitating the effect of 5-HT and SSRIs on motor learning [48] and are defective in patients with RTT and mouse models of the pathology [10,49]. The long half-life of fluoxetine and its active metabolite (6 and 12 h, respectively [50]) ensures prolonged exposure to the drug during the course of treatment. The half-lives of TRP and 5-HTP are short and their effects in rodents generally last a few hours or less [23,24,40,51,52]. Thus, it cannot be excluded that the failure of 5-HT precursors to improve motor coordination reflects their short-lived effect on brain 5-HT. However, the effectiveness of citalopram in improving motor coordination of Mecp2 Het mice despite its short half-life (about 1.5 h [53]) argues against this interpretation. This suggests that factors other than duration of action could account for the different ability of 5-HT precursors and SSRIs to improve motor coordination in Mecp2 Het mice.
Restoration of Mecp2 expression globally or selectively in the striatum is sufficient to rescue rotarod impairment in Mecp2 Het mice [54]. This suggests that the improvement in motor coordination produced by SSRIs likely reflects their ability to promote MeCP2 expression in several brain areas of the Mecp2 Het mouse, including the striatum [4,17]. If this effect is not shared by 5-HT precursors, it could explain their ineffectiveness on motor coordination. Further studies are needed to confirm this hypothesis.
In summary, current data show that 5-HT precursors alone are not effective in improving motor coordination of Mecp2 Het mice. TRP has no effect alone, but potentiates the antidepressant-like effect of SSRIs [33,55,56]. Therefore, it would be important to explore the possibility that, although ineffective alone, 5-HT precursors may improve the effect of SSRIs on motor coordination in RTT mice.

Author Contributions

Conceptualization, R.W.I.; data curation, C.V.; methodology, C.V. and R.W.I.; validation, R.W.I., C.V. and G.S.; formal analysis, R.W.I. and C.V.; investigation, C.V. and G.S.; resources, G.S. and C.V.; supervision, R.W.I.; validation, C.V. and R.W.I.; visualization, C.V. and R.W.I.; writing—original draft preparation, R.W.I.; writing—review and editing, R.W.I., C.V. and G.S. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by intramural resources and an economic contribution of the Associazione Amici del Mario Negri.

Institutional Review Board Statement

The “Istituto di Ricerche Farmacologiche Mario Negri IRCCS” adheres to the principles set out in the following law, regulations and policies governing the care and use of laboratory animals. Italian Governing Law (D.lgs.26/2014; Authorization n. 19/2008-A issued on 6 March 2008 by Ministry of Health); “Mario Negri” Institutional Regulations and Policies providing internal authorization for persons conducting animal experiments (Quality Management System Certificate—UNI EN ISO 9001:2008—Reg. N° 6121); the NIH Guide for the Care and Use of Laboratory Animals (2011 edition) and EU directives and guidelines (EEC Council Directive 2010/63/UE). All experimental protocols were approved by the Ministry of Health (Authorization n. 1087/2020-PR (6 November 2020) and n. 196/2022-PR (8 March 2022)).

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions presented in the study are included in the article; further inquiries can be directed to the corresponding author/s. The raw data can be downloaded at: https://zenodo.org/uploads/13134000.

Acknowledgments

We thank M. Carli for her advice and suggestions on this study and critical review of the manuscript, A. Di Clemente for his contribution to biochemical studies and C. Vigato for help with the graphical abstract.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Amir, R.E.; Van den Veyver, I.B.; Wan, M.; Tran, C.Q.; Francke, U.; Zoghbi, H.Y. Rett Syndrome Is Caused by Mutations in X-Linked MECP2, Encoding Methyl-CpG-Binding Protein 2. Nat. Genet. 1999, 23, 185–188. [Google Scholar] [CrossRef] [PubMed]
  2. Lombardi, L.M.; Baker, S.A.; Zoghbi, H. MECP2 Disorders: From the Clinic to Mice and Back. J. Clin. Investig. 2015, 125, 2914–2923. [Google Scholar] [CrossRef] [PubMed]
  3. Samaco, R.C.; Mandel-Brehm, C.; Chao, H.-T.; Ward, C.S.; Fyffe-Maricich, S.L.; Ren, J.; Hyland, K.; Thaller, C.; Maricich, S.M.; Humphreys, P.; et al. Loss of MeCP2 in Aminergic Neurons Causes Cell-Autonomous Defects in Neurotransmitter Synthesis and Specific Behavioral Abnormalities. Proc. Natl. Acad. Sci. USA 2009, 106, 21966–21971. [Google Scholar] [CrossRef] [PubMed]
  4. Villani, C.; Sacchetti, G.; Carli, M.; Invernizzi, R.W. Fluoxetine Rescues Rotarod Motor Deficits in Mecp2 Heterozygous Mouse Model of Rett Syndrome via Brain Serotonin. Neuropharmacology 2020, 176, 108221. [Google Scholar] [CrossRef] [PubMed]
  5. Philippe, T.J.; Vahid-Ansari, F.; Donaldson, Z.R.; Le François, B.; Zahrai, A.; Turcotte-Cardin, V.; Daigle, M.; James, J.; Hen, R.; Merali, Z.; et al. Loss of MeCP2 in Adult 5-HT Neurons Induces 5-HT1A Autoreceptors, with Opposite Sex-Dependent Anxiety and Depression Phenotypes. Sci. Rep. 2018, 8, 5788. [Google Scholar] [CrossRef] [PubMed]
  6. Santos, M.; Summavielle, T.; Teixeira-Castro, A.; Silva-Fernandes, A.; Duarte-Silva, S.; Marques, F.; Martins, L.; Dierssen, M.; Oliveira, P.; Sousa, N.; et al. Monoamine Deficits in the Brain of Methyl-CpG Binding Protein 2 Null Mice Suggest the Involvement of the Cerebral Cortex in Early Stages of Rett Syndrome. Neuroscience 2010, 170, 453–467. [Google Scholar] [CrossRef] [PubMed]
  7. Panayotis, N.; Ghata, A.; Villard, L.; Roux, J.C. Biogenic Amines and Their Metabolites Are Differentially Affected in the Mecp2-Deficient Mouse Brain. BMC Neurosci. 2011, 12, 47. [Google Scholar] [CrossRef] [PubMed]
  8. Vogelgesang, S.; Niebert, S.; Renner, U.; Möbius, W.; Hülsmann, S.; Manzke, T.; Niebert, M. Analysis of the Serotonergic System in a Mouse Model of Rett Syndrome Reveals Unusual Upregulation of Serotonin Receptor 5b. Front. Mol. Neurosci. 2017, 10, 61. [Google Scholar] [CrossRef] [PubMed]
  9. Isoda, K.; Morimoto, M.; Matsui, F.; Hasegawa, T.; Tozawa, T.; Morioka, S.; Chiyonobu, T.; Nishimura, A.; Yoshimoto, K.; Hosoi, H. Postnatal Changes in Serotonergic Innervation to the Hippocampus of Methyl-CpG-Binding Protein 2-Null Mice. Neuroscience 2010, 165, 1254–1260. [Google Scholar] [CrossRef]
  10. De Filippis, B.; Musto, M.; Altabella, L.; Romano, E.; Canese, R.; Laviola, G. Deficient Purposeful Use of Forepaws in Female Mice Modelling Rett Syndrome. Neural Plast. 2015, 2015, 326184. [Google Scholar] [CrossRef]
  11. Abdala, A.P.; Bissonnette, J.M.; Newman-Tancredi, A. Pinpointing Brainstem Mechanisms Responsible for Autonomic Dysfunction in Rett Syndrome: Therapeutic Perspectives for 5-HT1A Agonists. Front. Physiol. 2014, 5, 205. [Google Scholar] [CrossRef] [PubMed]
  12. Flores Gutiérrez, J.; De Felice, C.; Natali, G.; Leoncini, S.; Signorini, C.; Hayek, J.; Tongiorgi, E. Protective Role of Mirtazapine in Adult Female Mecp2+/− Mice and Patients with Rett Syndrome. J. Neurodev. Disord. 2020, 12, 26. [Google Scholar] [CrossRef] [PubMed]
  13. Gokben, S.; Ardic, U.A.; Serdaroglu, G. Use of Buspirone and Fluoxetine for Breathing Problems in Rett Syndrome. Pediatr. Neurol. 2012, 46, 192–194. [Google Scholar] [CrossRef] [PubMed]
  14. Ohno, K.; Saito, Y.; Ueda, R.; Togawa, M.; Ohmae, T.; Matsuda, E.; Fujiyama, M.; Maegaki, Y. Effect of Serotonin 1A Agonists and Selective Serotonin Reuptake Inhibitors on Behavioral and Nighttime Respiratory Symptoms in Rett Syndrome. Pediatr. Neurol. 2016, 60, 54–59. [Google Scholar] [CrossRef] [PubMed]
  15. Temudo, T.; Rios, M.; Prior, C.; Carrilho, I.; Santos, M.; Maciel, P.; Sequeiros, J.; Fonseca, M.; Monteiro, J.; Cabral, P.; et al. Evaluation of CSF Neurotransmitters and Folate in 25 Patients with Rett Disorder and Effects of Treatment. Brain Dev. 2009, 31, 46–51. [Google Scholar] [CrossRef]
  16. Persico, A.M.; Ricciardello, A.; Cucinotta, F. The Psychopharmacology of Autism Spectrum Disorder and Rett Syndrome. In Handbook of Clinical Neurology; Elsevier: Amsterdam, The Netherlands, 2019; Volume 165, pp. 391–414. ISBN 978-0-444-64012-3. [Google Scholar]
  17. Villani, C.; Carli, M.; Castaldo, A.M.; Sacchetti, G.; Invernizzi, R.W. Fluoxetine Increases Brain MeCP2 Immuno-Positive Cells in a Female Mecp2 Heterozygous Mouse Model of Rett Syndrome through Endogenous Serotonin. Sci. Rep. 2021, 11, 14690. [Google Scholar] [CrossRef]
  18. Bianchi, M.T. Non-Serotonin Anti-Depressant Actions: Direct Ion Channel Modulation by SSRIs and the Concept of Single Agent Poly-Pharmacy. Med. Hypotheses 2008, 70, 951–956. [Google Scholar] [CrossRef]
  19. Pinna, G.; Costa, E.; Guidotti, A. SSRIs Act as Selective Brain Steroidogenic Stimulants (SBSSs) at Low Doses That Are Inactive on 5-HT Reuptake. Curr. Opin. Pharmacol. 2009, 9, 24–30. [Google Scholar] [CrossRef]
  20. Walther, D.J.; Peter, J.U.; Bashammakh, S.; Hortnagl, H.; Voits, M.; Fink, H.; Bader, M. Synthesis of Serotonin by a Second Tryptophan Hydroxylase Isoform. Science 2003, 299, 76. [Google Scholar] [CrossRef]
  21. Gijsman, H.J.; van Gerven, J.M.A.; de Kam, M.L.; Schoemaker, R.C.; Pieters, M.S.M.; Weemaes, M.; de Rijk, R.; van der Post, J.; Cohen, A.F. Placebo-Controlled Comparison of Three Dose-Regimens of 5-Hydroxytryptophan Challenge Test in Healthy Volunteers. J. Clin. Psychopharmacol. 2002, 22, 183–189. [Google Scholar] [CrossRef]
  22. Green, A.R.; Aronson, J.K.; Curzon, G.; Woods, H.F. Metabolism of an Oral Tryptophan Load. I: Effects of Dose and Pretreatment with Tryptophan. Br. J. Clin. Pharmacol. 1980, 10, 603–610. [Google Scholar] [CrossRef] [PubMed]
  23. Sarna, G.S.; Hutson, P.H.; O’Connell, M.T.; Curzon, G. Effect of Tryptophan on Extracellular Concentrations of Tryptophan and 5-Hydroxyindoleacetic Acid in the Striatum and Cerebellum. J. Neurochem. 1991, 56, 1564–1568. [Google Scholar] [CrossRef] [PubMed]
  24. Jacobsen, J.P.; Rudder, M.L.; Roberts, W.; Royer, E.L.; Robinson, T.J.; Oh, A.; Spasojevic, I.; Sachs, B.D.; Caron, M.G. SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2016, 41, 2324–2334. [Google Scholar] [CrossRef] [PubMed]
  25. Heine, W.; Radke, M.; Wutzke, K.D.; Peters, E.; Kundt, G. Alpha-Lactalbumin-Enriched Low-Protein Infant Formulas: A Comparison to Breast Milk Feeding. Acta Paediatr. 1996, 85, 1024–1028. [Google Scholar] [CrossRef]
  26. Petersen, H.; Nomayo, A.; Zelenka, R.; Foster, J.; Tvrdík, J.; Jochum, F. Adequacy and Safety of α-Lactalbumin-Enriched Low-Protein Infant Formula: A Randomized Controlled Trial. Nutrition 2020, 74, 110728. [Google Scholar] [CrossRef]
  27. Dupont, C.; Rivero, M.; Grillon, C.; Belaroussi, N.; Kalindjian, A.; Marin, V. Alpha-Lactalbumin-Enriched and Probiotic-Supplemented Infant Formula in Infants with Colic: Growth and Gastrointestinal Tolerance. Eur. J. Clin. Nutr. 2010, 64, 765–767. [Google Scholar] [CrossRef]
  28. Choi, S.; DiSilvio, B.; Fernstrom, M.H.; Fernstrom, J.D. Meal Ingestion, Amino Acids and Brain Neurotransmitters: Effects of Dietary Protein Source on Serotonin and Catecholamine Synthesis Rates. Physiol. Behav. 2009, 98, 156–162. [Google Scholar] [CrossRef]
  29. Orosco, M.; Rouch, C.; Beslot, F.; Feurte, S.; Regnault, A.; Dauge, V. Alpha-Lactalbumin-Enriched Diets Enhance Serotonin Release and Induce Anxiolytic and Rewarding Effects in the Rat. Behav. Brain Res. 2004, 148, 1–10. [Google Scholar] [CrossRef]
  30. De Caro, C.; Leo, A.; Nesci, V.; Ghelardini, C.; di Cesare Mannelli, L.; Striano, P.; Avagliano, C.; Calignano, A.; Mainardi, P.; Constanti, A.; et al. Intestinal Inflammation Increases Convulsant Activity and Reduces Antiepileptic Drug Efficacy in a Mouse Model of Epilepsy. Sci. Rep. 2019, 9, 13983. [Google Scholar] [CrossRef]
  31. Citraro, R.; Scicchitano, F.; De Fazio, S.; Raggio, R.; Mainardi, P.; Perucca, E.; De Sarro, G.; Russo, E. Preclinical Activity Profile of α-Lactoalbumin, a Whey Protein Rich in Tryptophan, in Rodent Models of Seizures and Epilepsy. Epilepsy Res. 2011, 95, 60–69. [Google Scholar] [CrossRef]
  32. Leo, A.; De Caro, C.; Mainardi, P.; Tallarico, M.; Nesci, V.; Marascio, N.; Striano, P.; Russo, E.; Constanti, A.; De Sarro, G.; et al. Increased Efficacy of Combining Prebiotic and Postbiotic in Mouse Models Relevant to Autism and Depression. Neuropharmacology 2021, 198, 108782. [Google Scholar] [CrossRef] [PubMed]
  33. Cervo, L.; Canetta, A.; Calcagno, E.; Burbassi, S.; Sacchetti, G.; Caccia, S.; Fracasso, C.; Albani, D.; Forloni, G.; Invernizzi, R.W. Genotype-Dependent Activity of Tryptophan Hydroxylase-2 Determines the Response to Citalopram in a Mouse Model of Depression. J. Neurosci. 2005, 25, 8165–8172. [Google Scholar] [CrossRef] [PubMed]
  34. Lasley, S.M.; Michaelson, I.A.; Greenland, R.D.; McGinnis, P.M. Simultaneous Measurement of Tyrosine, Tryptophan and Related Monoamines for Determination of Neurotransmitter Turnover in Discrete Rat Brain Regions by Liquid Chromatography with Electrochemical Detection. J. Chromatogr. 1984, 305, 27–42. [Google Scholar] [CrossRef] [PubMed]
  35. Isingrini, E.; Perret, L.; Rainer, Q.; Sagueby, S.; Moquin, L.; Gratton, A.; Giros, B. Selective Genetic Disruption of Dopaminergic, Serotonergic and Noradrenergic Neurotransmission: Insights into Motor, Emotional and Addictive Behaviour. J. Psychiatry Neurosci. JPN 2016, 41, 169–181. [Google Scholar] [CrossRef]
  36. Carlsson, A.; Davis, J.N.; Kehr, W.; Lindqvist, M.; Atack, C.V. Simultaneous Measurement of Tyrosine and Tryptophan Hydroxylase Activities in Brain In Vivo Using an Inhibitor of the Aromatic Amino Acid Decarboxylase. Naunyn Schmiedeberg’s Arch. Pharmacol. 1972, 275, 153–168. [Google Scholar] [CrossRef]
  37. Carli, M.; Kostoula, C.; Sacchetti, G.; Mainolfi, P.; Anastasia, A.; Villani, C.; Invernizzi, R.W. Tph2 Gene Deletion Enhances Amphetamine-Induced Hypermotility: Effect of 5-HT Restoration and Role of Striatal Noradrenaline Release. J. Neurochem. 2015, 135, 674–685. [Google Scholar] [CrossRef]
  38. Baumann, M.H.; Williams, Z.; Zolkowska, D.; Rothman, R.B. Serotonin (5-HT) Precursor Loading with 5-Hydroxy-L-Tryptophan (5-HTP) Reduces Locomotor Activation Produced by (+)-Amphetamine in the Rat. Drug Alcohol. Depend. 2011, 114, 147–152. [Google Scholar] [CrossRef]
  39. Westerink, B.H.; De Vries, J.B. Effect of Precursor Loading on the Synthesis Rate and Release of Dopamine and Serotonin in the Striatum: A Microdialysis Study in Conscious Rats. J. Neurochem. 1991, 56, 228–233. [Google Scholar] [CrossRef]
  40. Carneiro, I.B.C.; Toscano, A.E.; Lacerda, D.C.; da Cunha, M.d.S.B.; de Castro, R.M.; Deiró, T.C.B.d.J.; Medeiros, J.M.B. L-Tryptophan Administration and Increase in Cerebral Serotonin Levels: Systematic Review. Eur. J. Pharmacol. 2018, 836, 129–135. [Google Scholar] [CrossRef]
  41. Perry, K.W.; Fuller, R.W. Extracellular 5-Hydroxytryptamine Concentration in Rat Hypothalamus after Administration of Fluoxetine plus L-5-Hydroxytryptophan. J. Pharm. Pharmacol. 1993, 45, 759–761. [Google Scholar] [CrossRef]
  42. Choi, S.; DiSilvio, B.; Fernstrom, M.H.; Fernstrom, J.D. Effect of Chronic Protein Ingestion on Tyrosine and Tryptophan Levels and Catecholamine and Serotonin Synthesis in Rat Brain. Nutr. Neurosci. 2011, 14, 260–267. [Google Scholar] [CrossRef]
  43. Reagan-Shaw, S.; Nihal, M.; Ahmad, N. Dose Translation from Animal to Human Studies Revisited. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2008, 22, 659–661. [Google Scholar] [CrossRef]
  44. Layman, D.K.; Lönnerdal, B.; Fernstrom, J.D. Applications for α-Lactalbumin in Human Nutrition. Nutr. Rev. 2018, 76, 444–460. [Google Scholar] [CrossRef]
  45. Gaspar, P.; Cases, O.; Maroteaux, L. The Developmental Role of Serotonin: News from Mouse Molecular Genetics. Nat. Rev. Neurosci. 2003, 4, 1002–1012. [Google Scholar] [CrossRef]
  46. Jing, J.-Q.; Jia, S.-J.; Yang, C.-J. Physical Activity Promotes Brain Development through Serotonin during Early Childhood. Neuroscience 2024, 554, 34–42. [Google Scholar] [CrossRef]
  47. Meijer, A.; Königs, M.; Vermeulen, G.T.; Visscher, C.; Bosker, R.J.; Hartman, E.; Oosterlaan, J. The Effects of Physical Activity on Brain Structure and Neurophysiological Functioning in Children: A Systematic Review and Meta-Analysis. Dev. Cogn. Neurosci. 2020, 45, 100828. [Google Scholar] [CrossRef] [PubMed]
  48. Vitrac, C.; Benoit-Marand, M. Monoaminergic Modulation of Motor Cortex Function. Front. Neural Circuits 2017, 11, 72. [Google Scholar] [CrossRef]
  49. FitzGerald, P.M.; Jankovic, J.; Glaze, D.G.; Schultz, R.; Percy, A.K. Extrapyramidal Involvement in Rett’s Syndrome. Neurology 1990, 40, 293–295. [Google Scholar] [CrossRef]
  50. Hirano, K.; Kimura, R.; Sugimoto, Y.; Yamada, J.; Uchida, S.; Kato, Y.; Hashimoto, H.; Yamada, S. Relationship between Brain Serotonin Transporter Binding, Plasma Concentration and Behavioural Effect of Selective Serotonin Reuptake Inhibitors. Br. J. Pharmacol. 2005, 144, 695–702. [Google Scholar] [CrossRef]
  51. Eccleston, D.; Ashcroft, G.W.; Crawford, T.B. 5-Hydroxyindole Metabolism in Rat Brain. A Study of Intermediate Metabolism Using the Technique of Tryptophan Loading. II. Applications and Drug Studies. J. Neurochem. 1965, 12, 493–503. [Google Scholar] [CrossRef]
  52. Ho, I.K.; Brase, D.A.; Loh, H.H.; Way, E.L. Influence of L-Tryptophan on Morphine Analgesia, Tolerance and Physical Dependence. J. Pharmacol. Exp. Ther. 1975, 193, 35–43. [Google Scholar] [PubMed]
  53. Fredricson Overø, K. Kinetics of Citalopram in Test Animals; Drug Exposure in Safety Studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 1982, 6, 297–309. [Google Scholar] [CrossRef] [PubMed]
  54. Su, S.-H.; Kao, F.-C.; Huang, Y.-B.; Liao, W. MeCP2 in the Rostral Striatum Maintains Local Dopamine Content Critical for Psychomotor Control. J. Neurosci. Off. J. Soc. Neurosci. 2015, 35, 6209–6220. [Google Scholar] [CrossRef] [PubMed]
  55. Guzzetti, S.; Calcagno, E.; Canetta, A.; Sacchetti, G.; Fracasso, C.; Caccia, S.; Cervo, L.; Invernizzi, R.W. Strain Differences in Paroxetine-Induced Reduction of Immobility Time in the Forced Swimming Test in Mice: Role of Serotonin. Eur. J. Pharmacol. 2008, 594, 117–124. [Google Scholar] [CrossRef]
  56. Calcagno, E.; Canetta, A.; Guzzetti, S.; Cervo, L.; Invernizzi, R.W. Strain Differences in Basal and Post-Citalopram Extracellular 5-HT in the Mouse Medial Prefrontal Cortex and Dorsal Hippocampus: Relation with Tryptophan Hydroxylase-2 Activity. J. Neurochem. 2007, 103, 1111–1120. [Google Scholar] [CrossRef]
Biomolecules 14 01230 g001
Figure 1. Schedule of treatment and timing of biochemical and behavioural assessments. Cohort 1 consisted of untreated wild type and Mecp2 Het mice used to assess differences in regional brain levels of 5-HT, 5-HIAA and TRP between genotypes (Table 1). Cohort 2a was used to assess the dose- and time-dependent effect of ALAC on brain levels of 5-HT, 5-HIAA and brain and plasma levels of TRP in WT mice (Figure 2 and Figure 3). Cohort 2b was used to determine whether ALAC (8000 mg/kg) had a similar effect on monoamines and TRP in WT and Mecp2 Het mice (Figure 4). Cohort 2c was used to assess the effect of a repeated treatment with TRP on brain indole and TRP levels (Table 2). Cohorts 3 and 4 were used to assess the effect of TRP (300 mg/kg i.p., once daily for 14 days), 5-HTP (100 mg/kg/day in drinking water) and ALAC (8000 mg/kg/day in drinking water) on motor coordination in WT and Mecp2 Het mice (Figure 5 and Figure 6). The black arrows indicate days from the start of treatment when rotarod performance was measured. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine; 5-HTP, 5-hydroxytryptophan; ALAC, α-lactalbumin; HET, Mecp2 heterozygous; HPLC, high performance liquid chromatography; MA, monoamines; TRP, tryptophan; WT, wild type.
Figure 1. Schedule of treatment and timing of biochemical and behavioural assessments. Cohort 1 consisted of untreated wild type and Mecp2 Het mice used to assess differences in regional brain levels of 5-HT, 5-HIAA and TRP between genotypes (Table 1). Cohort 2a was used to assess the dose- and time-dependent effect of ALAC on brain levels of 5-HT, 5-HIAA and brain and plasma levels of TRP in WT mice (Figure 2 and Figure 3). Cohort 2b was used to determine whether ALAC (8000 mg/kg) had a similar effect on monoamines and TRP in WT and Mecp2 Het mice (Figure 4). Cohort 2c was used to assess the effect of a repeated treatment with TRP on brain indole and TRP levels (Table 2). Cohorts 3 and 4 were used to assess the effect of TRP (300 mg/kg i.p., once daily for 14 days), 5-HTP (100 mg/kg/day in drinking water) and ALAC (8000 mg/kg/day in drinking water) on motor coordination in WT and Mecp2 Het mice (Figure 5 and Figure 6). The black arrows indicate days from the start of treatment when rotarod performance was measured. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine; 5-HTP, 5-hydroxytryptophan; ALAC, α-lactalbumin; HET, Mecp2 heterozygous; HPLC, high performance liquid chromatography; MA, monoamines; TRP, tryptophan; WT, wild type.
Biomolecules 14 01230 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Villani, C.; Sacchetti, G.; Invernizzi, R.W. Boosting Serotonin Synthesis Is Not Sufficient to Improve Motor Coordination of Mecp2 Heterozygous Mouse Model of Rett Syndrome. Biomolecules 2024, 14, 1230. https://doi.org/10.3390/biom14101230

AMA Style

Villani C, Sacchetti G, Invernizzi RW. Boosting Serotonin Synthesis Is Not Sufficient to Improve Motor Coordination of Mecp2 Heterozygous Mouse Model of Rett Syndrome. Biomolecules. 2024; 14(10):1230. https://doi.org/10.3390/biom14101230

Chicago/Turabian Style

Villani, Claudia, Giuseppina Sacchetti, and Roberto W. Invernizzi. 2024. "Boosting Serotonin Synthesis Is Not Sufficient to Improve Motor Coordination of Mecp2 Heterozygous Mouse Model of Rett Syndrome" Biomolecules 14, no. 10: 1230. https://doi.org/10.3390/biom14101230

APA Style

Villani, C., Sacchetti, G., & Invernizzi, R. W. (2024). Boosting Serotonin Synthesis Is Not Sufficient to Improve Motor Coordination of Mecp2 Heterozygous Mouse Model of Rett Syndrome. Biomolecules, 14(10), 1230. https://doi.org/10.3390/biom14101230

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop